A comprehensive characterization of mucocutaneous adverse events (MAEs) has not been performed; therefore, we characterized MAEs associated with the selective RET inhibitor, selpercatinib.<h4>Methods</h4>We assessed 133 patients with <i>RET-</i>altered cancers treated with selpercatinib. This evidence concerns the gene RET and cancer.